Three Reasons Why Biotech Turnarounds are so Hard

It’s difficult to imagine anyone launching a biotech company in anticipation of it stalling and becoming a turnaround three or five years later. Still, many companies find themselves just a few years after launch in a position where growth (if there was any) has stagnated and raising capital is increasingly difficult. In our experience there are three reasons why biotech turnarounds are so hard.